Abstract 152P
Background
Nanoliposomal irinotecan with fluorouracil and folinic acid (Nal-IRI/FU/LV; NFF) is a standard treatment after gemcitabine-based chemotherapy for unresectable pancreatic cancer (uPC) patients (pts). However, there has been no data comparing safety between prior biliary drainage (BD) and non-BD (NBD). Therefore, we conducted such a study and report the results of the interim sub-analysis.
Methods
As part of a pre-planned interim analysis of a multicenter prospective observational study from June 2021, we analyzed the patient characteristics and clinical outcomes of uPC pts associated with safety; adverse events (AEs), dose modification, and relative dose intensity between patients in the BD and NBD groups. This analysis was conducted on attaining 50% of the target cases.
Results
The median follow-up period was 5.3 months. Of the 75 pts, NFF was administered to the 19 pts in the BD group and the 56 pts in the NBD group. The BD group was significantly younger (p=0.049), included more locally advanced disease (p=0.04) and pancreatic head cases (p<0.01), and the duration of their previous treatment was shorter (p=0.02) compared with the NBD group. The median relative dose intensities in the BD and NBD groups of Nal-IRI were 78.1% and 69.8% (p=0.21) and of FU 89.9% and 80.4% (p=0.23), respectively. For the initial dose, 42% and 59% of pts in the BD and NBD groups needed Nal-IRI dose reduction, respectively (p=0.53). The rates of dose reduction during NFF did not differ in Nal-IRI or in FU, and those of discontinuation of NFF due to AEs were similar in the two groups (7% vs 8%). The rate of grade 3/4 non-hematological AEs was higher in the BD group (63% vs 30%; p=0.01), whereas that of hematological AEs was equivalent (32% vs 32%; p=0.96). Frequent grade 3/4 AEs in the BD group were neutropenia (26%), anemia (16%), and fatigue (15%). Additionally, biliary tract infections were observed only in the BD group (16%, p<0.01).
Conclusions
NFF more frequently caused severe non-hematological AEs and biliary tract infections in the BD group. Therefore, more attention should be paid to pts with prior BD for safety.
Clinical trial identification
Editorial acknowledgement
We thank Robert Blakytny, DPhil, from Edanz for editing a draft of this abstract.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract